Research on individualisation of tacrolimus regimen based on the CYP3A5, MDR1 and PXR genotype-guided combination therapy (coadministration with diltiazem or Schisandra sphenanthera extract): a randomised controlled trial.
Phase of Trial: Phase III
Latest Information Update: 24 Feb 2013
At a glance
- Drugs Tacrolimus (Primary) ; Diltiazem
- Indications Renal transplant rejection
- Focus Pharmacogenomic; Pharmacokinetics
- 04 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 29 Sep 2009 New trial record